Drug-induced kidney disease in HIV-infected patients: clinical variants, approaches to prevention


Cite item

Full Text

Abstract

Renal disease in HIV-patients , associated with highly active antiretroviral therapy, it's clinical variants and approaches to diagnosis and prevention are discussed

About the authors

N A Mukhin

V V Fomin

References

  1. Winston J.A. HIV and CKD epidemiology. Adv. Chronic Kidney Dis. 2010; 17(1): 19-25
  2. Gupta S.K., Eustace J.A., Winston J.A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2005; 40: 1559-1585
  3. Berns J.S., Kasbekar N. Highly active antiretroviral therapy and the kidney: and update on antiretroviral medications for nephrologists. Clin. J. Am. Soc. Nephrol. 2006; 1: 117-129
  4. Perazella M.A. Acute renal failure in HIV-infected patients: a brief review of common causes. Am. J. Med. Sci. 2000; 319(6): 385-391
  5. Izzedine H., Baumelou A., Deray G. Acute renal failure in HIV patients. Nephrol. Dial. Transplant. 2007; 22: 2757 - 2762
  6. Franceschini N., Napravnik S., Eron J.J. et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005; 67: 1526 - 1531
  7. Wyatt C.M., Arons R.R., Klotman P.E., Klotman M.E. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 204561 - 204565
  8. Peraldi M.N., Maslo C., Akposso K. et al. Acute renal failure in the course of retrospective study of ninety-two patients and sixty renal biopsies. Nephrol. Dial. Transplant. 1999; 14(6): 1578-1585.
  9. Nicolau Laparra M.C., Martínez F., Giner V. et al. Temporal evolution of renal involvement in a necropsy study of HIV patients from the pre and HAART eras. Nefrologia. 2010; 30(4): 420-426
  10. Joshi M.K., Liu H.H. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care STDS. 2000; 14(10): 541-548
  11. Roe J., Campbell L.J., Ibrahim F. et al. HIV care and the incidence of acute renal failure. Clin. Infect. Dis. 2008; 47(2): 242-249
  12. Overton E.T., Nurutdinova D., Freeman J. et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009; 10(6): 343-350
  13. Ibrahim F., Naftalin C., Cheserem E. et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010; 24(14): 2239-2244
  14. Crum-Cianflone N., Ganesan A., Teneza-Mora N. et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010; 24(6): 353-360
  15. Izzedine H., Hulot J.S., Vittecoq D. et al. Study 903 Team. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. 2005; 20: 743 - 746
  16. Barrios A., García-Benayas T., González-Lahoz J., Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004; 18(6): 960-963
  17. Gallant J.E., Winston J.A., DeJesus E. et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008; 22(16): 2155-2163
  18. Mauss S., Berger F., Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 93-95
  19. Madeddu G., Bonfanti P., De Socio G.V. et al.; CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed. Pharmacother. 2008; 62(1): 6-11
  20. Jones R., Wolf E., Hoffmann C., Procaccianti M. et al. Long-term consequences of treatment interruptions in chronically HIV-1 infected patients. Eur. J. Med. Res. 2005; 10(2): 56-62
  21. Jones R., Stebbing J., Nelson M. et al. Renal dysfunction with tenofovir DF containing HAART regimens is not observed more frequently: a cohort and case-control study. J. AIDS 2001; 37: 1489 - 1495
  22. Psevdos G. Jr., Gonzalez E., Sharp V. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read. 2009; 19(6): 245-248
  23. Riordan A., Judd A., Boyd K. et al.; Collaborative HIV Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr. Infect. Dis. J. 2009; 28(3): 204-209
  24. Bpharm S.M., Talbot A., Trottier B. et al. Acute renal failure in four HIV-infected patients: Potential association with tenofovir and nonsteroidal anti-inflammatory drugs. Can. J. Infect. Dis. Med. Microbiol. 2008; 19(1): 75-76
  25. Izzedine H., Launay-Vacher V., Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005; 19: 455 - 462
  26. Quimby D., Brito M.O. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005; 15(7): 357-364
  27. Badiou S., De Boever C.M., Terrier N. et al. Is tenofovir involved in hypophosphatemia and decrease in tubular prosphate reabsorbtion in HIV-positive adults? J. Infect. 2006; 52: 335-338
  28. Harmouche H., Le Bras P., Bignani O. et al. Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir. Rev. Med. Interne. 2005; 26(6): 522-523
  29. Callens S., De Roo A., Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J. Infect. 2003; 47(3): 262-263
  30. D'Ythurbide G., Goujard C., Méchaï F. et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol. Dial. Transplant. 2007; 22(12): 3656-3659
  31. de la Prada F.J., Prados A.M., Tugores A. et al. Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia. 2006; 26(5): 626-630
  32. Hall A.M., Hendry B.M., Nitsch D., Connolly J.O. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am. J. Kidney Dis. 2011; 57(5): 773-780
  33. Gatanaga H., Tachikawa N., Kikuchi Y. et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses. 2006; 22(8): 744-748
  34. Izzedine H., Launay-Vacher V., Aymard G. et al. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001; 89(1): 62-67
  35. Post F.A., Moyle G.J., Stellbrink H.J. et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J. Acquir. Immune Defic. Syndr. 2010; 55(1): 49-57

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies